FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308398106> ?p ?o ?g. }

• W4308398106 abstract "<h3>Background</h3> We previously identified WNT/β-catenin (<i>CTNNB1</i>) and an atlas of molecular alterations that drive the non-T cell-inflamed phenotype and immune-checkpoint inhibitor (ICI) resistance across cancers. To refine our analysis, we have subsequently separated tumor types by clinically relevant stratifications, such as human papilloma virus (HPV) in head and neck squamous cell carcinoma (HNSCC), to identify immune-exclusion mechanisms associated with specific patient populations. P38 MAPK is a known regulator of dendritic cells (DCs) and myeloid cells however a tumor-intrinsic immunomodulatory role has not been previously described. <h3>Methods</h3> Using the T cell-inflamed gene expression signature we previously defined, we integrated tissue RNAseq from 395 HPV- HNSCCs in The Cancer Genome Atlas (TCGA) with single-cell RNAseq from two independent HNSCC studies. We detected differentially expressed genes in non-T cell-inflamed <i>versus</i> inflamed tumors by limma voom (v3.36) in concert with causal network prediction, followed by validation in two independent HNSCC cohorts. scRNAseq data was processed by Cellranger (v6) and Seurat (v3.99). We quantified pathway expression levels in tumor cells, DCs, macrophages, and other main cell types in the tumor microenvironment. Single-cell pathway comparisons were further conducted using generalized linear mixed-effects models (GLMM) and protein-protein interaction networks constructed by STRING. Pharmacologic inhibition of p38 MAPK was explored in combination with ICI in two syngeneic murine models. Patients with ICI refractory tumors were treated with p38 inhibitor plus ICI. <h3>Results</h3> We identified 67 pathways as activated in non-T cell-inflamed tumors from the HPV- cohort of HNSCC, 59 of which were independently validated. This included CTNNB1 from our prior work and p38 MAPK, the therapeutic target in our ongoing clinical trial (NCT04074967). CTNNB1 and p38 pathway molecules both showed inverse correlation with CD8A protein abundance from the Clinical Proteomic Tumor Analysis Consortium. We observed a significant enrichment of pathway expression only in tumor cells (p<0.05) from both HNSCC scRNAseq studies and dominantly in non-T cell-inflamed tumors. Using an accumulative scoring system integrating bulk tissue and single cell sequencing data, we prioritized seven pathways as strongly connected in non-inflamed tumors, with the top regulators as CTNNB1 and p38, among others. EMT6 and CT26 syngeneic murine models demonstrated improved survival with the addition of p38 inhibitor to ICI relative to ICI monotherapy. Major and durable clinical responses have been observed in patients with anti-PD1 refractory tumors. Conclusions p38 is a novel tumor-intrinsic mechanism that drives immune exclusion. P38 inhibition enhances ICI and can overcome anti-PD1 resistance in patients. <h3>Ethics Approval</h3> Our study gained approval from IRB, HCC#19-097. Any/all participants in human studies gave informed consent before participating." @default.
• W4308398106 created "2022-11-11" @default.
• W4308398106 creator A5014963329 @default.
• W4308398106 creator A5015094097 @default.
• W4308398106 creator A5018707169 @default.
• W4308398106 creator A5026264123 @default.
• W4308398106 creator A5044898944 @default.
• W4308398106 creator A5063337705 @default.
• W4308398106 creator A5081911362 @default.
• W4308398106 creator A5082943927 @default.
• W4308398106 creator A5086074491 @default.
• W4308398106 date "2022-11-01" @default.
• W4308398106 modified "2023-10-12" @default.
• W4308398106 title "908 Tumor-intrinsic p38 signaling as a therapeutic target to overcome non-T cell-inflamed tumors and immunotherapy resistance" @default.
• W4308398106 doi "https://doi.org/10.1136/jitc-2022-sitc2022.0908" @default.
• W4308398106 hasPublicationYear "2022" @default.
• W4308398106 type Work @default.
• W4308398106 citedByCount "0" @default.
• W4308398106 crossrefType "proceedings-article" @default.
• W4308398106 hasAuthorship W4308398106A5014963329 @default.
• W4308398106 hasAuthorship W4308398106A5015094097 @default.
• W4308398106 hasAuthorship W4308398106A5018707169 @default.
• W4308398106 hasAuthorship W4308398106A5026264123 @default.
• W4308398106 hasAuthorship W4308398106A5044898944 @default.
• W4308398106 hasAuthorship W4308398106A5063337705 @default.
• W4308398106 hasAuthorship W4308398106A5081911362 @default.
• W4308398106 hasAuthorship W4308398106A5082943927 @default.
• W4308398106 hasAuthorship W4308398106A5086074491 @default.
• W4308398106 hasBestOaLocation W43083981061 @default.
• W4308398106 hasConcept C121608353 @default.
• W4308398106 hasConcept C137620995 @default.
• W4308398106 hasConcept C1491633281 @default.
• W4308398106 hasConcept C203014093 @default.
• W4308398106 hasConcept C2776090121 @default.
• W4308398106 hasConcept C2776107976 @default.
• W4308398106 hasConcept C2776530083 @default.
• W4308398106 hasConcept C2776833033 @default.
• W4308398106 hasConcept C2777701055 @default.
• W4308398106 hasConcept C2780851360 @default.
• W4308398106 hasConcept C502942594 @default.
• W4308398106 hasConcept C54355233 @default.
• W4308398106 hasConcept C62478195 @default.
• W4308398106 hasConcept C86803240 @default.
• W4308398106 hasConcept C8891405 @default.
• W4308398106 hasConcept C95444343 @default.
• W4308398106 hasConceptScore W4308398106C121608353 @default.
• W4308398106 hasConceptScore W4308398106C137620995 @default.
• W4308398106 hasConceptScore W4308398106C1491633281 @default.
• W4308398106 hasConceptScore W4308398106C203014093 @default.
• W4308398106 hasConceptScore W4308398106C2776090121 @default.
• W4308398106 hasConceptScore W4308398106C2776107976 @default.
• W4308398106 hasConceptScore W4308398106C2776530083 @default.
• W4308398106 hasConceptScore W4308398106C2776833033 @default.
• W4308398106 hasConceptScore W4308398106C2777701055 @default.
• W4308398106 hasConceptScore W4308398106C2780851360 @default.
• W4308398106 hasConceptScore W4308398106C502942594 @default.
• W4308398106 hasConceptScore W4308398106C54355233 @default.
• W4308398106 hasConceptScore W4308398106C62478195 @default.
• W4308398106 hasConceptScore W4308398106C86803240 @default.
• W4308398106 hasConceptScore W4308398106C8891405 @default.
• W4308398106 hasConceptScore W4308398106C95444343 @default.
• W4308398106 hasLocation W43083981061 @default.
• W4308398106 hasOpenAccess W4308398106 @default.
• W4308398106 hasPrimaryLocation W43083981061 @default.
• W4308398106 hasRelatedWork W3011094612 @default.
• W4308398106 hasRelatedWork W3039388108 @default.
• W4308398106 hasRelatedWork W3081408373 @default.
• W4308398106 hasRelatedWork W3177607563 @default.
• W4308398106 hasRelatedWork W4200189496 @default.
• W4308398106 hasRelatedWork W4248668835 @default.
• W4308398106 hasRelatedWork W4285222832 @default.
• W4308398106 hasRelatedWork W4285731353 @default.
• W4308398106 hasRelatedWork W4317612392 @default.
• W4308398106 hasRelatedWork W4378715746 @default.
• W4308398106 isParatext "false" @default.
• W4308398106 isRetracted "false" @default.
• W4308398106 workType "article" @default.